Quick Links: Skip to main page content
Skip to Search
Skip to Topics Menu
Skip to Common Links
U.S. Food & Drug Administration
Follow FDA
En Español
Search FDA
Home
Food
Drugs
Medical Devices
Radiation-Emitting Products
Vaccines, Blood & Biologics
Animal & Veterinary
Cosmetics
Tobacco Products
New Pediatric Labeling Information Database - Detail
FDA Home
Pediatrics
New Pediatric Labeling Information Database
Detail
-
Please note:
JavaScript must be enabled for this application to work properly.
Check your settings
if you are unsure if your JavaScript is enabled.
Pediatric Labeling Date:
08/28/2009
Trade Name:
Valcyte
Generic Name or Proper Name (*):
valganciclovir
Indications Studied:
Prevention of cytomegalovirus (CMV) disease in pediatric kidney and heart transplant patients e 4 months of age
Label Changes Summary:
Use in pediatric patients e 4 months is based on efficacy data from a study in adults and PK, safety, and efficacy data from an open-label trial in pediatric solid organ transplant recipients at risk for developing CMV disease The efficacy and safety have not been established in children for: 1.Prevention of CMV disease in liver transplant patients 2.Prevention of CMV disease in solid organ transplants other than those indicated 3.Prevention of CMV disease in pediatric solid organ transplant patients < 4 months of age 4.Treatment of congenital CMV disease Adverse events (AEs) similar to adult patients, however, certain Aes including upper respiratory tract infection, pyrexia, nasopharyngitis, anemia, and neutropenia were reported more frequently in pediatric patients Information on dosing, PK, and clinical study New dosage form
Product Labeling:
Labeling
BPCA(B) and PREA(P):
B, P
Sponsor:
Roche
Pediatric Exclusivity Granted Date:
07/24/2008
NNPS:
FALSE'
Therapeutic Category:
Antiviral
-
-